(0)

DIA会员及用户请点击登录

登录

忘记用户 ID？ or 忘记密码？

Not a Member?

创建账户并加入。

Ottawa Marriott Hotel

2017 年 10 月 16 日 7:00 上午 - 2017 年 10 月 16 日 5:00 下午

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

Canadian Pharmacovigilance and Risk Management Strategies Conference

概览

DIA’s Canadian Pharmacovigilance and Risk Management Strategies Conference is the premier place to hear from expert pharmaceutical, biotechnology, and regulatory personnel about Global Regulatory Guidance Document updates (pharmacovigilance, risk management, and drug safety), gain new perspectives from the Inspectorate, and discuss patient support programs and PV responsibilities. Join in on an exclusive session with the Canadian regulator, touching on a host of current topics including the management of Canada Vigilance Adverse Reaction Online Database duplicate safety reports.

On-Demand Complimentary Webinar

Plain Language Labeling for Over-the-Counter Drugs: Implementing Health Canada’s Guidance for Industry
On-Demand
This webinar will review Health Canada’s requirements for Plain Language Labeling for over-the-counter medicines. Presenters will walk through key recently finalized and revised guidance documents to help industry comply with these requirements and identify strategies to help industry add Drug Facts Tables to packaging while minimizing the need for packaging increases. Register today!

DIA's Canadian Health Care Content Roundup

NEW! This year DIA's Canadian Pharmacovigilance and Risk Management Conference will be co-located with the DIA Canadian Annual Meeting. Maximize your education and time by attending both!
While our conference is currently in development, check out last year’s program to see what’s in store!
View Program.

Featured

Want to learn more about Canadian Pharmacovigilance and Risk Management Strategies Conference? You've come to the right site!

Continuing-Education

了解更多

谁应该参加？

Professionals involved in:

  • Advertising and Promotion
  • Biotechnology
  • Clinical Data Management/eClinical
  • CMC
  • Combination Products
  • Clinical Safety and Pharmacovigilance
  • Clinical Research
  • Medical Devices and Diagnostics
  • Pharmacology
  • Regulatory Affairs

学习目标

At the conclusion of this activity, participants should be able to:

  • Describe the current Canadian regulatory framework for pharmacovigilance
  • Examine current Pharmacovigilance issues facing Marketing Authorization Holders in Canada
  • Discuss proposed changes to Vanessa’s Law
  • Identify strategies for implementing benefit-risk analyses and risk management plans

项目委员会

  • Rita Cassola, RPh
    Rita Cassola, RPh Executive Director PV
    Certus PV Services Inc, Canada
  • Marcia Bailey, BSN, MHS, RN
    Marcia Bailey, BSN, MHS, RN Safety Evaluation and Risk Management Scientific Director
    GSK, Canada
  • Colin D'Cunha, MD, MHS, FRCPC
    Colin D'Cunha, MD, MHS, FRCPC Director, Global Medical Affairs
    Apotex Inc., Canada
  • Ljubica Ivanisevic, PhD
    Ljubica Ivanisevic, PhD Scientific Evaluator
    Health Canada, Canada
  • Marc Poitras, PhD, MBA
    Marc Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    Health Canada, Canada

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表，了解DIA的观点和事件。